血管介入治疗在中晚期肝癌综合治疗中的角色  

Application of hepatic arterial infusion chemotherapy in multidisciplinary comprehensive treatment of hepatocellular carcionma

作　　者：潘扬勋 陈敏山[1] PAN Yangxun;CHEN Minshan(Department of Liver Surgery,Sun Yat-sen University Cancer Center,Guangzhou 510060,China)

机构地区：[1]中山大学肿瘤防治中心肝脏外科,广州510060

出　　处：《科技导报》2023年第18期52-57,共6页Science & Technology Review

摘　　要：原发性肝癌是最常见的消化道恶性肿瘤之一,其发病率及肿瘤相关死亡率常年位于中国恶性肿瘤的前列。肝动脉灌注化疗(HAIC)作为近几年受到越来越多关注的有中国特色的血管介入治疗,其在中晚期肝癌综合治疗中所扮演的角色和作用方兴未艾。概括了HAIC在中晚期肝癌患者的多学科综合治疗中扮演的角色,并从多学科综合治疗的角度分析了其和国内外指南推荐的肝动脉化疗栓塞(TACE)对于治疗中晚期肝癌的优劣。Primary liver cancer(HCC)is one of the most common malignant tumors of the digestive tract,and its incidence and tumor-related mortality rank among the forefront of malignant tumors in China for years.Hepatic arterial infusion chemotherapy(HAIC),as a vascular interventional therapy with Chinese characteristics that has received more and more attention in recent years,is playing an ascendant role in the comprehensive treatment of intermediate-to-advanced stage HCC.The current article reviewed HAIC as an important treatment method in the multidisciplinary comprehensive treatment of HCC patients at the intermediate-to-advanced stage and discussed the effects of HAIC and hepatic arterial chemoembolization recommended by guidelines on the treatment of intermediate-to-advanced stage HCC from the perspective of multidisciplinary comprehensive treatment,and wish to provide theoretical guidance for the future multidisciplinary clinical practice of intermediate-to-advanced stage HCC based on vascular interventional therapy.

关 键 词：肝癌 介入治疗 肝动脉灌注化疗 肝动脉化疗栓塞 综合治疗 

分 类 号：R735.7[医药卫生—肿瘤]